Cigna, Humana See COVID Costs Creep Up in Fourth Quarter

Although the COVID-19 pandemic has had a largely positive impact on health insurers’ bottom lines — given the sheer magnitude of deferred routine and elective care — two publicly traded payers’ recent fourth-quarter earnings results show that they are not immune from the myriad costs associated with the case surge that occurred in the fall and winter of 2020.

Cigna Corp., which reported its fourth-quarter and full-year 2020 financial results on Feb. 4, posted an adjusted earnings per share (EPS) of $3.51, missing the consensus Wall Street estimate of $3.68 because of “higher COVID cost in the quarter,” as Citi analyst Ralph Giacobbe put it. Most of that pressure was felt in the company’s U.S. Medical segment — which houses its commercial and government-sponsored insurance businesses — as fourth-quarter adjusted income from operations and adjusted margins both declined year over year due to COVID-19 and the one year-return of the health insurance fee.

0 Comments
© 2022 MMIT
Leslie Small

Leslie Small

Leslie has been reporting and editing in various journalism roles for nearly a decade. Most recently, she was the senior editor of FierceHealthPayer, an e-newsletter covering the health insurance industry. A graduate of Penn State University, she previously served in editing roles at newspapers in Pennsylvania, Virginia and Colorado.

Related Posts

call-center
May 20

Marketplace, MCOs Will Face a Rocky Transition When PHE Ends

READ MORE
exec-pointing-at-graphs
May 20

Startups Oscar Health, Bright Health Exit Markets & Tighten Belts

READ MORE
humana-logo
May 20

Humana Doubles Down on Primary Care Clinic Investments

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today